(Q33696575)

28 July 2017

Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir (English)

1 reference

28 July 2017

1 reference

1 reference

2

1 reference

28 July 2017

Emma Andrews

1

1 reference

28 July 2017

Juanzhi Fang

3

1 reference

28 July 2017

Penelope Crownover

4

1 reference

28 July 2017

Randall Tressler

5

1 reference

28 July 2017

Bharat Damle

6

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

British Journal of Clinical Pharmacology

28 July 2017

1 reference

28 July 2017

69

1 reference

28 July 2017

1

1 reference

28 July 2017

51-57

1 reference

HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations

28 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2830597

Raltegravir: the first HIV integrase inhibitor

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2830597

Review of HIV antiretroviral drug resistance

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2830597

Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2830597

Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2830597

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2830597

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2830597

Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2830597

Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2830597

Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2830597

Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid–liquid extraction and HPLC-MS/MS

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20078612

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1365-2125.2009.03546.X

1 reference

28 July 2017

1 reference

28 July 2017

1 reference